Condition
Pheochromocytoma/Paraganglioma (PPGL)
Total Trials
3
Recruiting
2
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
P 2 (1)
Trial Status
Recruiting2
Enrolling By Invitation1
Clinical Trials (3)
Showing 3 of 3 trials
NCT06503146Phase 2Recruiting
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
NCT07288931Not ApplicableRecruitingPrimary
Al18F-NOTA-LM3 PET/CT in Patients With Pheochromocytoma and Paraganglioma
NCT07182175Enrolling By Invitation
Comparative Study of Perioperative Cardiac Injury in Patients With Functional Adrenal Tumors
Showing all 3 trials